SCHEMBL5032065

SCHEMBL5032065

CCONC(=O)N(c1ccccc1)c1ncc2cn[nH]c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
FLT3 P36888 1/20 0.34
CCNE2 O96020 4/20 0.34
CCNE1 P24864 4/20 0.34
CDK2 P24941 4/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
GAA P10253 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
RPS6KB1 P23443 1/20 0.32
PDGFRB P09619 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015656 0.87 CSF1R (0.39) CSF1RHDAC1HDAC6FLT3CCNE2
SCHEMBL83293 0.85 GSK3A (0.38) CSF1RHDAC1HDAC6CCNE2CCNE1
SCHEMBL5032062 0.84 HDAC1 (0.34) HDAC1HDAC6CCNE2CCNE1CDK2
SCHEMBL82345 0.83 CSF1R (0.39) CSF1RHDAC1HDAC6FLT3CCNE2
SCHEMBL5027077 0.83 HDAC6 (0.36) CSF1RHDAC1HDAC6CCNE2CCNE1
SCHEMBL5013510 0.82 CSF1R (0.38) CSF1RHDAC1HDAC6FLT3CCNE2
SCHEMBL5014883 0.82 CSF1R (0.36) CSF1RHDAC1HDAC6FLT3CCNE2
SCHEMBL5027708 0.81 HDAC6 (0.39) HDAC1HDAC6CCNE2CCNE1CDK2
SCHEMBL81783 0.80 CSF1R (0.40) CSF1RHDAC1HDAC6FLT3CCNE2
SCHEMBL79935 0.80 CSF1R (0.39) CSF1RHDAC1HDAC6FLT3CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234262-A1 PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS WYETH (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234262-A1 PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS MTOR, PIK3CA, PDPK1 CSF1R 3094/4885HDAC1 680/4885HDAC6 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.